Kalp Yetersizliklerinde Sezaryen Anestezisi

Authors

Nuray Altay

Synopsis

Physiological increases in plasma volume and cardiac output during pregnancy can trigger underlying cardiac conditions, leading to heart failure (HF) that increases maternal and fetal morbidity and mortality. HF in pregnancy frequently stems from peripartum cardiomyopathy, valvular heart diseases, congenital heart diseases, and ischemic heart diseases. Risk assessment models such as NYHA, CARPREG I, CARPREG II, ZAHARA, and the WHO risk stratification model are utilized to evaluate cardiovascular risks in pregnant women, with the WHO model demonstrating the best performance in predicting maternal complications. For the highest-risk pregnant patients, planned cesarean delivery with multidisciplinary birth planning is preferred to avoid emergency situations. In anesthetic management, neuraxial anesthesia (spinal, epidural, or combined spinal-epidural [CSE]) is preferred because it protects against the risks of general anesthesia and positive-pressure ventilation, with sequential CSE techniques frequently applied to provide a gradual hemodynamic onset alongside a symmetrical block. Conversely, general anesthesia becomes mandatory for patients with an epidural hematoma risk due to anticoagulant use, those developing pulmonary edema, or hemodynamically unstable patients; remifentanil premedication and etomidate induction can be preferred to attenuate cardiovascular responses to intubation. Invasive monitoring, including intra-arterial catheters, central venous catheters, and TEE, is of vital importance. In the postpartum period, BNP levels (<100 pg/ml) possess a high negative predictive value for distinguishing clinical conditions, while continuous follow-up by a multidisciplinary team consisting of cardiologists, obstetricians, perinatologists, and anesthesiologists remains fundamental in reducing maternal mortality.

References

Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104: 2996-3007

Aronow WS, Ahn C, Kronzon I, et al. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 1991; 67: 295-9

Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics and whites. Am J Cardiol 1999; 84: 611-12

Garovic VD, Bailey KR, Boerwinkle E, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens 2010;28:826–33.

Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br Heart J 1992;68:540–3.

Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515–21.

Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;17:2124–32.

Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006;113:517–24.

Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147–97.

Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12:767–78.

Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native valves. J Am Coll Cardiol 2005;46:223–30.

Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001;37:893–9.

Silversides CK, Colman JM, Sermer M, et al. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol 2003;91:1382–5.

Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy; The task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147–97.

Connolly HM. Pregnancy in women with congenital heart disease.Curr Cardiol Rep 2005;7:305–9.

Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart 2006;92:1520–5.

Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2017;135:e50–87.

Lindley KJ, Conner SN, Cahill AG, et al. Contraception and pregnancy planning in women with congenital heart disease. Curr Treat Options Cardiovasc Med 2015;17:50.

Clark AL, Sparrow JL, Coats AJ. Muscle fatigue and dyspnoea in chronic heart failure: two sides of the same coin? Eur Heart J 1995;16:49-52.

Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2005;46:e1-82.

Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515–21.

Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;31:2124–32.

Silversides CK, Grewal J, Mason J, et al. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol 2018;71:2419–30.

Balci A, Sollie-Szarynska KM, van der Bijl AG, et al. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart 2014;100:1373–81.

Lindley KJ, Conner SN, Cahill AG. Adult congenital heart disease in pregnancy. Obstet Gynecol Surv 2015;70:397–407.

Langesaeter E, Dragsund M, Rosseland LA. Regional anaesthesia for a Caesarean section in women with cardiac disease: a prospective study. Acta Anaesthesiol Scand 2010;54:46–54.

Arendt KWMJ, Tsen LT. Cardiovascular alterations in the parturient undergoing cesarean delivery with neuraxial anesthesia. Exp Rev Obstet Gynecol 2014;7:59–75.

Hamlyn EL, Douglass CA, Plaat F, et al. Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease. Int J Obstet Anesth 2005;14:355–61.

Dresner M, Pinder A. Anaesthesia for caesarean section in women with complex cardiac disease: 34 cases using the Braun Spinocath spinal catheter. Int J Obstet Anesth 2009;18:131-6.

Abildgaard U, Sandset PM, Hammerstrom J, et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009;124:262–7.

Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191–6.

Ngan Kee WD, Khaw KS, Ma KC, et al. Maternal and neonatal effects of remifentanil at induction of general anesthesia for cesarean delivery: a randomized, doubleblind, controlled trial. Anesthesiology 2006;104:14–20.

Heesen M, Klohr S, Hofmann T, et al. Maternal and foetal effects of remifentanil for general anaesthesia in parturients undergoing caesarean section: a systematic review and meta-analysis. Acta Anaesthesiol Scand 2013;57:29–36.

Wadsworth R, Greer R, MacDonald JM, et al. The use of remifentanil during general anaesthesia for caesarean delivery in two patients with severe heart dysfunction. Int J Obstet Anesth 2002;11:38–43.

Manullang TR, Chun K, Egan TD. The use of remifentanil for cesarean section in a parturient with recurrent aortic coarctation. Can J Anaesth 2000;47:454–9.

Orme RM, Grange CS, Ainsworth QP, et al. General anaesthesia using remifentanil for caesarean section in parturients with critical aortic stenosis: a series of four cases. Int J Obstet Anesth 2004;13:183–7.

Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009;15:645–50.

Mhyre JM, D’Oria R, Hameed AB, et al. The maternal early warning criteria: a proposal from the national partnership for maternal safety. Obstet Gynecol 2014;124:782–6.

Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:1247–53.

Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005;193:450–4.

Pages

143-152

Published

November 17, 2021

License

License